4th Annual MS Lung Cancer Roundtable Meeting - November 7-8, 2025

Question Title

* 1. Please select which of the following best describes your primary role.

CEO

COO / Deputy Director

CFO / Finance Director

Pharmacist

Physician / Medical Director

Nurse Practitioner

Nurse (RN)

Nurse (LPN)

Social Worker

Other (please specify)

Question Title

* 2. On a scale of 1 to 5, with 1 being NOT SATISFIED and 5 being VERY SATISFIED, please rate your level of satisfaction with each of the following:

	1 - Not Satisfied	2 - Somewhat satisfied	3 - Neutral	4 - Satisfied	5 - Very Satisfied
Relevance of information to your needs.	Relevance of information to your needs. 1 - Not Satisfied	Relevance of information to your needs. 2 - Somewhat satisfied	Relevance of information to your needs. 3 - Neutral	Relevance of information to your needs. 4 - Satisfied	Relevance of information to your needs. 5 - Very Satisfied
Presentation quality of instructor(s).	Presentation quality of instructor(s). 1 - Not Satisfied	Presentation quality of instructor(s). 2 - Somewhat satisfied	Presentation quality of instructor(s). 3 - Neutral	Presentation quality of instructor(s). 4 - Satisfied	Presentation quality of instructor(s). 5 - Very Satisfied
Subject matter knowledge of instructor(s).	Subject matter knowledge of instructor(s). 1 - Not Satisfied	Subject matter knowledge of instructor(s). 2 - Somewhat satisfied	Subject matter knowledge of instructor(s). 3 - Neutral	Subject matter knowledge of instructor(s). 4 - Satisfied	Subject matter knowledge of instructor(s). 5 - Very Satisfied
Training facilities or webinar platform.	Training facilities or webinar platform. 1 - Not Satisfied	Training facilities or webinar platform. 2 - Somewhat satisfied	Training facilities or webinar platform. 3 - Neutral	Training facilities or webinar platform. 4 - Satisfied	Training facilities or webinar platform. 5 - Very Satisfied
Instructor's engagement and response to questions.	Instructor's engagement and response to questions. 1 - Not Satisfied	Instructor's engagement and response to questions. 2 - Somewhat satisfied	Instructor's engagement and response to questions. 3 - Neutral	Instructor's engagement and response to questions. 4 - Satisfied	Instructor's engagement and response to questions. 5 - Very Satisfied
Overall quality of the training/workshop.	Overall quality of the training/workshop. 1 - Not Satisfied	Overall quality of the training/workshop. 2 - Somewhat satisfied	Overall quality of the training/workshop. 3 - Neutral	Overall quality of the training/workshop. 4 - Satisfied	Overall quality of the training/workshop. 5 - Very Satisfied

Question Title

* 3. General Sessions
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following BEFORE the training.

	1 - Very Low	2 - Low	3 - Moderate	4 - High	5 - Very High
The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective.	The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective. 1 - Very Low	The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective. 2 - Low	The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective. 3 - Moderate	The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective. 4 - High	The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective. 5 - Very High
Update on screening for lung cancer in the U.S.	Update on screening for lung cancer in the U.S. 1 - Very Low	Update on screening for lung cancer in the U.S. 2 - Low	Update on screening for lung cancer in the U.S. 3 - Moderate	Update on screening for lung cancer in the U.S. 4 - High	Update on screening for lung cancer in the U.S. 5 - Very High
Challenges in uptake, adherence, and disparities.	Challenges in uptake, adherence, and disparities. 1 - Very Low	Challenges in uptake, adherence, and disparities. 2 - Low	Challenges in uptake, adherence, and disparities. 3 - Moderate	Challenges in uptake, adherence, and disparities. 4 - High	Challenges in uptake, adherence, and disparities. 5 - Very High
The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship.	The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship. 1 - Very Low	The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship. 2 - Low	The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship. 3 - Moderate	The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship. 4 - High	The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship. 5 - Very High
Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care.	Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care. 1 - Very Low	Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care. 2 - Low	Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care. 3 - Moderate	Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care. 4 - High	Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care. 5 - Very High
The applications of AI in detection of those at risk for lung cancer.	The applications of AI in detection of those at risk for lung cancer. 1 - Very Low	The applications of AI in detection of those at risk for lung cancer. 2 - Low	The applications of AI in detection of those at risk for lung cancer. 3 - Moderate	The applications of AI in detection of those at risk for lung cancer. 4 - High	The applications of AI in detection of those at risk for lung cancer. 5 - Very High
The applications of AI in stratification of those at risk for lung cancer.	The applications of AI in stratification of those at risk for lung cancer. 1 - Very Low	The applications of AI in stratification of those at risk for lung cancer. 2 - Low	The applications of AI in stratification of those at risk for lung cancer. 3 - Moderate	The applications of AI in stratification of those at risk for lung cancer. 4 - High	The applications of AI in stratification of those at risk for lung cancer. 5 - Very High
The SYBIL model for predicting future lung cancer risk.	The SYBIL model for predicting future lung cancer risk. 1 - Very Low	The SYBIL model for predicting future lung cancer risk. 2 - Low	The SYBIL model for predicting future lung cancer risk. 3 - Moderate	The SYBIL model for predicting future lung cancer risk. 4 - High	The SYBIL model for predicting future lung cancer risk. 5 - Very High
Integration of the SYBIL model into lung cancer screening and risk assessment strategies.	Integration of the SYBIL model into lung cancer screening and risk assessment strategies. 1 - Very Low	Integration of the SYBIL model into lung cancer screening and risk assessment strategies. 2 - Low	Integration of the SYBIL model into lung cancer screening and risk assessment strategies. 3 - Moderate	Integration of the SYBIL model into lung cancer screening and risk assessment strategies. 4 - High	Integration of the SYBIL model into lung cancer screening and risk assessment strategies. 5 - Very High

Question Title

* 4. General Sessions
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following AFTER the training.

	1 - Very Low	2 - Low	3 - Moderate	4 - High	5 - Very High
The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective.	The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective. 1 - Very Low	The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective. 2 - Low	The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective. 3 - Moderate	The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective. 4 - High	The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective. 5 - Very High
Update on screening for lung cancer in the U.S.	Update on screening for lung cancer in the U.S. 1 - Very Low	Update on screening for lung cancer in the U.S. 2 - Low	Update on screening for lung cancer in the U.S. 3 - Moderate	Update on screening for lung cancer in the U.S. 4 - High	Update on screening for lung cancer in the U.S. 5 - Very High
Challenges in uptake, adherence, and disparities.	Challenges in uptake, adherence, and disparities. 1 - Very Low	Challenges in uptake, adherence, and disparities. 2 - Low	Challenges in uptake, adherence, and disparities. 3 - Moderate	Challenges in uptake, adherence, and disparities. 4 - High	Challenges in uptake, adherence, and disparities. 5 - Very High
The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship.	The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship. 1 - Very Low	The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship. 2 - Low	The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship. 3 - Moderate	The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship. 4 - High	The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship. 5 - Very High
Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care.	Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care. 1 - Very Low	Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care. 2 - Low	Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care. 3 - Moderate	Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care. 4 - High	Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care. 5 - Very High
The applications of AI in detection of those at risk for lung cancer.	The applications of AI in detection of those at risk for lung cancer. 1 - Very Low	The applications of AI in detection of those at risk for lung cancer. 2 - Low	The applications of AI in detection of those at risk for lung cancer. 3 - Moderate	The applications of AI in detection of those at risk for lung cancer. 4 - High	The applications of AI in detection of those at risk for lung cancer. 5 - Very High
The applications of AI in stratification of those at risk for lung cancer.	The applications of AI in stratification of those at risk for lung cancer. 1 - Very Low	The applications of AI in stratification of those at risk for lung cancer. 2 - Low	The applications of AI in stratification of those at risk for lung cancer. 3 - Moderate	The applications of AI in stratification of those at risk for lung cancer. 4 - High	The applications of AI in stratification of those at risk for lung cancer. 5 - Very High
The SYBIL model for predicting future lung cancer risk.	The SYBIL model for predicting future lung cancer risk. 1 - Very Low	The SYBIL model for predicting future lung cancer risk. 2 - Low	The SYBIL model for predicting future lung cancer risk. 3 - Moderate	The SYBIL model for predicting future lung cancer risk. 4 - High	The SYBIL model for predicting future lung cancer risk. 5 - Very High
Integration of the SYBIL model into lung cancer screening and risk assessment strategies.	Integration of the SYBIL model into lung cancer screening and risk assessment strategies. 1 - Very Low	Integration of the SYBIL model into lung cancer screening and risk assessment strategies. 2 - Low	Integration of the SYBIL model into lung cancer screening and risk assessment strategies. 3 - Moderate	Integration of the SYBIL model into lung cancer screening and risk assessment strategies. 4 - High	Integration of the SYBIL model into lung cancer screening and risk assessment strategies. 5 - Very High

Question Title

* 5. HEALTH PROFESSIONAL TRACK
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following BEFORE the training.

	1 - Very Low	2 - Low	3 - Moderate	4 - High	5 - Very High
The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC).	The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC). 1 - Very Low	The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC). 2 - Low	The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC). 3 - Moderate	The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC). 4 - High	The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC). 5 - Very High
The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC.	The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC. 1 - Very Low	The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC. 2 - Low	The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC. 3 - Moderate	The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC. 4 - High	The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC. 5 - Very High
Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules.	Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules. 1 - Very Low	Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules. 2 - Low	Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules. 3 - Moderate	Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules. 4 - High	Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules. 5 - Very High
Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules.	Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules. 1 - Very Low	Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules. 2 - Low	Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules. 3 - Moderate	Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules. 4 - High	Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules. 5 - Very High
The current standard of care and guidelines for staging of SCLC	The current standard of care and guidelines for staging of SCLC 1 - Very Low	The current standard of care and guidelines for staging of SCLC 2 - Low	The current standard of care and guidelines for staging of SCLC 3 - Moderate	The current standard of care and guidelines for staging of SCLC 4 - High	The current standard of care and guidelines for staging of SCLC 5 - Very High
The role of surgery in SCLC.	The role of surgery in SCLC. 1 - Very Low	The role of surgery in SCLC. 2 - Low	The role of surgery in SCLC. 3 - Moderate	The role of surgery in SCLC. 4 - High	The role of surgery in SCLC. 5 - Very High
The new systemic therapy options for small cell lung cancer patients.	The new systemic therapy options for small cell lung cancer patients. 1 - Very Low	The new systemic therapy options for small cell lung cancer patients. 2 - Low	The new systemic therapy options for small cell lung cancer patients. 3 - Moderate	The new systemic therapy options for small cell lung cancer patients. 4 - High	The new systemic therapy options for small cell lung cancer patients. 5 - Very High
Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy.	Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy. 1 - Very Low	Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy. 2 - Low	Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy. 3 - Moderate	Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy. 4 - High	Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy. 5 - Very High

Question Title

* 6. HEALTH PROFESSIONAL TRACK
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following AFTER the training.

	1 - Very Low	2 - Low	3 - Moderate	4 - High	5 - Very High
The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC).	The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC). 1 - Very Low	The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC). 2 - Low	The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC). 3 - Moderate	The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC). 4 - High	The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC). 5 - Very High
The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC.	The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC. 1 - Very Low	The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC. 2 - Low	The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC. 3 - Moderate	The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC. 4 - High	The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC. 5 - Very High
Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules.	Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules. 1 - Very Low	Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules. 2 - Low	Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules. 3 - Moderate	Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules. 4 - High	Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules. 5 - Very High
Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules.	Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules. 1 - Very Low	Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules. 2 - Low	Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules. 3 - Moderate	Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules. 4 - High	Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules. 5 - Very High
The current standard of care and guidelines for staging of SCLC	The current standard of care and guidelines for staging of SCLC 1 - Very Low	The current standard of care and guidelines for staging of SCLC 2 - Low	The current standard of care and guidelines for staging of SCLC 3 - Moderate	The current standard of care and guidelines for staging of SCLC 4 - High	The current standard of care and guidelines for staging of SCLC 5 - Very High
The role of surgery in SCLC.	The role of surgery in SCLC. 1 - Very Low	The role of surgery in SCLC. 2 - Low	The role of surgery in SCLC. 3 - Moderate	The role of surgery in SCLC. 4 - High	The role of surgery in SCLC. 5 - Very High
The new systemic therapy options for small cell lung cancer patients.	The new systemic therapy options for small cell lung cancer patients. 1 - Very Low	The new systemic therapy options for small cell lung cancer patients. 2 - Low	The new systemic therapy options for small cell lung cancer patients. 3 - Moderate	The new systemic therapy options for small cell lung cancer patients. 4 - High	The new systemic therapy options for small cell lung cancer patients. 5 - Very High
Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy.	Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy. 1 - Very Low	Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy. 2 - Low	Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy. 3 - Moderate	Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy. 4 - High	Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy. 5 - Very High

Question Title

* 7. COMMUNITY TRACK
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following BEFORE the training.

	1 - Very Low	2 - Low	3 - Moderate	4 - High	5 - Very High
Communicating lung cancer prevention messages to diverse communities.	Communicating lung cancer prevention messages to diverse communities. 1 - Very Low	Communicating lung cancer prevention messages to diverse communities. 2 - Low	Communicating lung cancer prevention messages to diverse communities. 3 - Moderate	Communicating lung cancer prevention messages to diverse communities. 4 - High	Communicating lung cancer prevention messages to diverse communities. 5 - Very High
Culturally responsive approaches to community engagement and health communication.	Culturally responsive approaches to community engagement and health communication. 1 - Very Low	Culturally responsive approaches to community engagement and health communication. 2 - Low	Culturally responsive approaches to community engagement and health communication. 3 - Moderate	Culturally responsive approaches to community engagement and health communication. 4 - High	Culturally responsive approaches to community engagement and health communication. 5 - Very High
Successful models of collaboration between community organizations and healthcare providers to address disparities.	Successful models of collaboration between community organizations and healthcare providers to address disparities. 1 - Very Low	Successful models of collaboration between community organizations and healthcare providers to address disparities. 2 - Low	Successful models of collaboration between community organizations and healthcare providers to address disparities. 3 - Moderate	Successful models of collaboration between community organizations and healthcare providers to address disparities. 4 - High	Successful models of collaboration between community organizations and healthcare providers to address disparities. 5 - Very High
The barriers that prevent communities from accessing lung cancer care and resources.	The barriers that prevent communities from accessing lung cancer care and resources. 1 - Very Low	The barriers that prevent communities from accessing lung cancer care and resources. 2 - Low	The barriers that prevent communities from accessing lung cancer care and resources. 3 - Moderate	The barriers that prevent communities from accessing lung cancer care and resources. 4 - High	The barriers that prevent communities from accessing lung cancer care and resources. 5 - Very High
Grassroots and statewide initiatives that improve trust and access.	Grassroots and statewide initiatives that improve trust and access. 1 - Very Low	Grassroots and statewide initiatives that improve trust and access. 2 - Low	Grassroots and statewide initiatives that improve trust and access. 3 - Moderate	Grassroots and statewide initiatives that improve trust and access. 4 - High	Grassroots and statewide initiatives that improve trust and access. 5 - Very High
The tools, programs, and partnerships available that support Mississippi communities.	The tools, programs, and partnerships available that support Mississippi communities. 1 - Very Low	The tools, programs, and partnerships available that support Mississippi communities. 2 - Low	The tools, programs, and partnerships available that support Mississippi communities. 3 - Moderate	The tools, programs, and partnerships available that support Mississippi communities. 4 - High	The tools, programs, and partnerships available that support Mississippi communities. 5 - Very High
The collaborative models across the lung cancer continuum.	The collaborative models across the lung cancer continuum. 1 - Very Low	The collaborative models across the lung cancer continuum. 2 - Low	The collaborative models across the lung cancer continuum. 3 - Moderate	The collaborative models across the lung cancer continuum. 4 - High	The collaborative models across the lung cancer continuum. 5 - Very High

Question Title

* 8. COMMUNITY TRACK
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following AFTER the training.

	1 - Very Low	2 - Low	3 - Moderate	4 - High	5 - Very High
Communicating lung cancer prevention messages to diverse communities.	Communicating lung cancer prevention messages to diverse communities. 1 - Very Low	Communicating lung cancer prevention messages to diverse communities. 2 - Low	Communicating lung cancer prevention messages to diverse communities. 3 - Moderate	Communicating lung cancer prevention messages to diverse communities. 4 - High	Communicating lung cancer prevention messages to diverse communities. 5 - Very High
Culturally responsive approaches to community engagement and health communication.	Culturally responsive approaches to community engagement and health communication. 1 - Very Low	Culturally responsive approaches to community engagement and health communication. 2 - Low	Culturally responsive approaches to community engagement and health communication. 3 - Moderate	Culturally responsive approaches to community engagement and health communication. 4 - High	Culturally responsive approaches to community engagement and health communication. 5 - Very High
Successful models of collaboration between community organizations and healthcare providers to address disparities.	Successful models of collaboration between community organizations and healthcare providers to address disparities. 1 - Very Low	Successful models of collaboration between community organizations and healthcare providers to address disparities. 2 - Low	Successful models of collaboration between community organizations and healthcare providers to address disparities. 3 - Moderate	Successful models of collaboration between community organizations and healthcare providers to address disparities. 4 - High	Successful models of collaboration between community organizations and healthcare providers to address disparities. 5 - Very High
The barriers that prevent communities from accessing lung cancer care and resources.	The barriers that prevent communities from accessing lung cancer care and resources. 1 - Very Low	The barriers that prevent communities from accessing lung cancer care and resources. 2 - Low	The barriers that prevent communities from accessing lung cancer care and resources. 3 - Moderate	The barriers that prevent communities from accessing lung cancer care and resources. 4 - High	The barriers that prevent communities from accessing lung cancer care and resources. 5 - Very High
Grassroots and statewide initiatives that improve trust and access.	Grassroots and statewide initiatives that improve trust and access. 1 - Very Low	Grassroots and statewide initiatives that improve trust and access. 2 - Low	Grassroots and statewide initiatives that improve trust and access. 3 - Moderate	Grassroots and statewide initiatives that improve trust and access. 4 - High	Grassroots and statewide initiatives that improve trust and access. 5 - Very High
The tools, programs, and partnerships available that support Mississippi communities.	The tools, programs, and partnerships available that support Mississippi communities. 1 - Very Low	The tools, programs, and partnerships available that support Mississippi communities. 2 - Low	The tools, programs, and partnerships available that support Mississippi communities. 3 - Moderate	The tools, programs, and partnerships available that support Mississippi communities. 4 - High	The tools, programs, and partnerships available that support Mississippi communities. 5 - Very High
The collaborative models across the lung cancer continuum.	The collaborative models across the lung cancer continuum. 1 - Very Low	The collaborative models across the lung cancer continuum. 2 - Low	The collaborative models across the lung cancer continuum. 3 - Moderate	The collaborative models across the lung cancer continuum. 4 - High	The collaborative models across the lung cancer continuum. 5 - Very High

Question Title

* 9. On a scale of 1 to 5, with 1 being NOT AT ALL LIKELY and 5 being EXTREMELY LIKELY, please rate how likely you are to do each of the following as a result of this training/workshop.

	1 - Not At All Likely	2 - Unlikel	3 - Undecided	4 - Likely	5 - Extremely Likely
Apply information from this workshop/training in your organization	Apply information from this workshop/training in your organization 1 - Not At All Likely	Apply information from this workshop/training in your organization 2 - Unlikel	Apply information from this workshop/training in your organization 3 - Undecided	Apply information from this workshop/training in your organization 4 - Likely	Apply information from this workshop/training in your organization 5 - Extremely Likely
Achieve the goals stated in this training/workshop	Achieve the goals stated in this training/workshop 1 - Not At All Likely	Achieve the goals stated in this training/workshop 2 - Unlikel	Achieve the goals stated in this training/workshop 3 - Undecided	Achieve the goals stated in this training/workshop 4 - Likely	Achieve the goals stated in this training/workshop 5 - Extremely Likely
Share this information with others within your organization	Share this information with others within your organization 1 - Not At All Likely	Share this information with others within your organization 2 - Unlikel	Share this information with others within your organization 3 - Undecided	Share this information with others within your organization 4 - Likely	Share this information with others within your organization 5 - Extremely Likely
Develop a plan to implement the desired change within your organization	Develop a plan to implement the desired change within your organization 1 - Not At All Likely	Develop a plan to implement the desired change within your organization 2 - Unlikel	Develop a plan to implement the desired change within your organization 3 - Undecided	Develop a plan to implement the desired change within your organization 4 - Likely	Develop a plan to implement the desired change within your organization 5 - Extremely Likely
Attend other trainings related to this topic	Attend other trainings related to this topic 1 - Not At All Likely	Attend other trainings related to this topic 2 - Unlikel	Attend other trainings related to this topic 3 - Undecided	Attend other trainings related to this topic 4 - Likely	Attend other trainings related to this topic 5 - Extremely Likely

Question Title

* 10. What actions do you plan to take to implement the knowledge you gained today?

Question Title

* 11. Did you detect any commercial bias?

Yes

No

Question Title

* 12. What did you like best about the 4th Annual MS Lung Cancer Roundtable?

Question Title

* 13. What can we do better or what was missing from the 4th Annual MS Lung Cancer Roundtable Meeting?

Question Title

* 14. Is there any other feedback you would like to share?